Reuters logo
BRIEF-Aptevo Therapeutics and Alligator Bioscience to co-develop novel bispecific antibody
July 21, 2017 / 5:15 AM / 2 months ago

BRIEF-Aptevo Therapeutics and Alligator Bioscience to co-develop novel bispecific antibody

July 21 (Reuters) - ALLIGATOR BIOSCIENCE AB

* APTEVO THERAPEUTICS AND ALLIGATOR BIOSCIENCE ANNOUNCE PLANS TO CO-DEVELOP NOVEL BISPECIFIC ANTIBODY FOR TUMOR-DIRECTED IMMUNOTHERAPY

* ‍PARTIES WILL JOINTLY OWN AND SHARE EQUALLY IN DEVELOPMENT COSTS ASSOCIATED WITH ADVANCING THIS CANDIDATE THROUGH TO END OF PHASE 2 CLINICAL DEVELOPMENT​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below